Tavapadon, a drug being tested to treat early Parkinson's disease, has shown great promise in a Phase III trial by AbbVie, ...

The progression of Parkinson's disease often requires a change of therapy. An expert explains when this should be done and ...

AbbVie's experimental drug to treat early Parkinson's disease met the main goal in a late-stage study, the drugmaker said on ...

AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...

Parkinson’s disease is a progressive neurological disorder in which ongoing changes in the brain affect and interfere with ...

A study from the University of Arizona shows that the protein PNA5 helps protect brain cells, offering a promising avenue for ...

AbbVie Inc. announced positive data from a third late-stage trial of a treatment for Parkinson’s disease on Monday and said it’s on track to seek approval for the drug from the Food and Drug ...

AbbVie Inc. (NYSE:ABBV) revealed topline results from its pivotal Phase 3 TEMPO-2 trial, which evaluated investigational ...

A new study published in the journal of Movement Disorders showed that Parkinson's disease (PD) was found to be independently ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...